The Breast IHC Panel (ER, PR, HER2, Ki-67) is a diagnostic test that uses immunohistochemistry (IHC) to evaluate the expression of specific proteins in breast cancer cells. The panel includes four markers: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67. The test results help classify breast cancer into different subtypes and guide treatment decisions.
Indications of the Test
The Breast IHC Panel is used to assess the expression of specific proteins in breast cancer cells. The test is often performed to determine the subtype of breast cancer and guide treatment decisions. ER and PR are used to determine the potential benefit of hormonal therapy, while HER2 is used to identify patients who may benefit from targeted therapy. Ki-67 is used to assess the aggressiveness of the cancer and guide treatment decisions.
No specific preparation is usually required for the Breast IHC Panel. However, it’s important to follow any instructions provided by the healthcare provider, especially regarding the use of medications that might affect the test results.
Typical Reference Values
The Breast IHC Panel evaluates the expression of four markers: ER, PR, HER2, and Ki-67. The results are interpreted based on established reference ranges for each marker.
The turnaround time for the Breast IHC Panel can vary depending on a number of factors. Typically, results are available within 10 working days. Expedited testing is available on request.
Order This Test
To order the Breast IHC Panel (ER, PR, HER2, Ki-67) test, please visit our website and search for the specific test name. You can then proceed with the online ordering process.